27452398|t|Protective effect of epigallocatechin-3-gallate (EGCG) via Nrf2 pathway against oxalate -induced epithelial mesenchymal transition (EMT) of renal tubular cells
27452398|a|This study evaluated effect of oxalate on epithelial mesenchymal transition (EMT) and potential anti-fibrotic property of epigallocatechin-3-gallate (EGCG). MDCK renal tubular cells were incubated with 0.5 mM sodium oxalate for 24-h with/without 1-h pretreatment with 25 Î¼M EGCG. Microscopic examination, immunoblotting and immunofluorescence staining revealed that oxalate -treated cells gained mesenchymal phenotypes by fibroblast -like morphological change and increasing expression of vimentin and fibronectin, while levels of epithelial markers (E-cadherin, occludin, cytokeratin and ZO-1) were decreased. EGCG pretreatment could prevent all these changes and molecular mechanisms underlying the prevention by EGCG were most likely due to reduced production of intracellular ROS through activation of Nrf2 signaling and increased catalase anti-oxidant enzyme. Knockdown of Nrf2 by small interfering RNA (siRNA) abrogated all the effects of EGCG, confirming that the EGCG protection against oxalate -induced EMT was mediated via Nrf2. Taken together, our data indicate that oxalate turned on EMT of renal tubular cells that could be prevented by EGCG via Nrf2 pathway. These findings also shed light onto development of novel therapeutics or preventive strategies of renal fibrosis in the future.
27452398	0	17	Protective effect	UnknownType	C0678771
27452398	21	47	epigallocatechin-3-gallate	T109,T121	C0059438
27452398	49	53	EGCG	T109,T121	C0059438
27452398	59	63	Nrf2	T116,T123	C0289507
27452398	64	71	pathway	T044	C1704259
27452398	80	87	oxalate	T109	C0029988
27452398	97	130	epithelial mesenchymal transition	T043	C1523298
27452398	132	135	EMT	T043	C1523298
27452398	140	145	renal	T023	C0022646
27452398	146	159	tubular cells	T025	C0552639
27452398	165	170	study	T062	C2603343
27452398	191	198	oxalate	T109	C0029988
27452398	202	235	epithelial mesenchymal transition	T043	C1523298
27452398	237	240	EMT	T043	C1523298
27452398	256	278	anti-fibrotic property	T033	C0243095
27452398	282	308	epigallocatechin-3-gallate	T109,T121	C0059438
27452398	310	314	EGCG	T109,T121	C0059438
27452398	317	341	MDCK renal tubular cells	T025	C0598829
27452398	347	356	incubated	T059	C0022885
27452398	369	383	sodium oxalate	T109	C0087001
27452398	410	422	pretreatment	T052	C3539076
27452398	434	438	EGCG	T109,T121	C0059438
27452398	440	463	Microscopic examination	T059	C0026018
27452398	465	479	immunoblotting	T059	C0020985
27452398	484	511	immunofluorescence staining	T059	C0079603
27452398	526	533	oxalate	T109	C0029988
27452398	543	548	cells	T025	C0007634
27452398	556	567	mesenchymal	T018	C0162415
27452398	568	578	phenotypes	T032	C0031437
27452398	582	592	fibroblast	T025	C0016030
27452398	599	619	morphological change	T190	C1260954
27452398	635	645	expression	T045	C1171362
27452398	649	657	vimentin	T116,T123	C0042666
27452398	662	673	fibronectin	T116,T123	C0016055
27452398	691	709	epithelial markers	T116,T123	C0033684
27452398	711	721	E-cadherin	T116,T123	C0042172
27452398	723	731	occludin	T116,T192	C0250400
27452398	733	744	cytokeratin	T116	C0010803
27452398	749	753	ZO-1	T116,T123	C3503764
27452398	771	775	EGCG	T109,T121	C0059438
27452398	776	788	pretreatment	T052	C3539076
27452398	825	845	molecular mechanisms	T044	C3537153
27452398	875	879	EGCG	T109,T121	C0059438
27452398	912	922	production	T038	C3714634
27452398	926	943	intracellular ROS	T123,T196	C0162772
27452398	952	962	activation	T052	C1879547
27452398	966	970	Nrf2	T116,T123	C0289507
27452398	971	980	signaling	T038	C3537152
27452398	995	1023	catalase anti-oxidant enzyme	T116,T126	C0007367
27452398	1025	1034	Knockdown	T063	C2350567
27452398	1038	1042	Nrf2	T028	C1417701
27452398	1046	1067	small interfering RNA	T114,T123	C1099354
27452398	1069	1074	siRNA	T114,T123	C1099354
27452398	1105	1109	EGCG	T109,T121	C0059438
27452398	1131	1135	EGCG	T109,T121	C0059438
27452398	1136	1146	protection	T033	C1545588
27452398	1155	1162	oxalate	T109	C0029988
27452398	1172	1175	EMT	T043	C1523298
27452398	1193	1197	Nrf2	T116,T123	C0289507
27452398	1238	1245	oxalate	T109	C0029988
27452398	1256	1259	EMT	T043	C1523298
27452398	1263	1268	renal	T023	C0022646
27452398	1269	1282	tubular cells	T025	C0552639
27452398	1310	1314	EGCG	T109,T121	C0059438
27452398	1319	1323	Nrf2	T116,T123	C0289507
27452398	1324	1331	pathway	T044	C1704259
27452398	1390	1402	therapeutics	T169	C0039798
27452398	1406	1427	preventive strategies	T080	C2700409
27452398	1431	1445	renal fibrosis	T047	C0151650